Amarin Co. plc (NASDAQ:AMRN – Get Free Report) saw a significant increase in short interest during the month of June. As of June 15th, there was short interest totalling 19,020,000 shares, an increase of 20.3% from the May 31st total of 15,810,000 shares. Based on an average daily trading volume, of 1,490,000 shares, the days-to-cover ratio is currently 12.8 days.
Amarin Stock Down 1.8 %
Shares of Amarin stock opened at $0.69 on Monday. Amarin has a 52 week low of $0.63 and a 52 week high of $1.49. The company has a market capitalization of $282.54 million, a PE ratio of -5.73 and a beta of 1.98. The stock’s fifty day moving average is $0.82 and its two-hundred day moving average is $0.95.
Amarin (NASDAQ:AMRN – Get Free Report) last posted its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.04) by $0.02. The company had revenue of $56.52 million for the quarter, compared to the consensus estimate of $51.34 million. Amarin had a negative net margin of 18.96% and a negative return on equity of 9.48%. During the same quarter last year, the firm posted ($0.04) EPS. As a group, research analysts anticipate that Amarin will post -0.18 earnings per share for the current year.
Institutional Trading of Amarin
Wall Street Analysts Forecast Growth
AMRN has been the topic of a number of analyst reports. StockNews.com cut shares of Amarin from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Amarin in a report on Tuesday, June 18th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, Amarin presently has an average rating of “Hold” and an average price target of $1.08.
Check Out Our Latest Stock Analysis on Amarin
Amarin Company Profile
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Further Reading
- Five stocks we like better than Amarin
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.